TY - JOUR T1 - Safely return to schools and offices: early and frequent screening with high sensitivity antigen tests effectively identifies COVID-19 patients JF - medRxiv DO - 10.1101/2021.10.08.21264782 SP - 2021.10.08.21264782 AU - Yong Dam Jeong AU - Keisuke Ejima AU - Kwang Su Kim AU - Shoya Iwanami AU - Shingo Iwami AU - Kazuyuki Aihara Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/11/2021.10.08.21264782.abstract N2 - Background In-person interaction at school and offices offers invaluable experience to students and benefits to companies. In the midst of the pandemic, ways to safely go back to schools and offices have been argued. Centers for Disease Control and Prevention (CDC) recommends taking all precautions such as vaccination and universal indoor masking. However, even if all the precautions are implemented and transmission is perfectly prevented in the facilities, they may be infected outside of the facilities, which would be a source of transmission in the facilities. Therefore, identifying those infected outside of the facility through screening is essential to safely go back to schools or offices. However, studies investigating the effectiveness of screening are limited. Further, it is not well clarified now which screening strategy (e.g., low or high sensitivity antigen tests, intervals and the number of tests) effectively identify infected and infectious individuals to avoid transmission in facilitiesMethods We assessed the effectiveness of various screening strategies in schools and offices through quantitative simulation. The effectiveness was assessed by the proportion of identified infected and infectious participants. Infection dynamics in the facility is governed by transmission dynamics of the population they belong to, and the screening is initiated at different epidemic phases: growth, peak, and declining phases. The viral load trajectory over time for each infected individual was modelled by the viral dynamics model, and the transmission process at the population level was modelled by a deterministic compartment model. The model parameters were estimated from clinical and epidemiological data. Screening strategies were varied by antigen tests with different sensitivity and schedules of screening over 10 days.Results Under the daily screening, we found high sensitivity antigen tests (the detection limit: 6.3 × 104 copies/mL) yielded 88% (95%CI 86-89) of effectiveness by the end of 10 days screening period, which is about 20% higher than that with low sensitivity antigen tests (2.0 × 106 copies/mL). Comparing screening scenarios with different schedules, we found early and frequent screening is the key to maximize the effectiveness. Sensitivity analysis revealed that less frequent tests might be an option when the number of antigen tests is limited especially when the screening is performed at the growth phase.Discussion High sensitivity antigen tests, high frequency screening, and immediate initiation of screening are the key to safely restart educational and economic activities allowing in-person interactions. Our computational framework is useful in assessment of screening strategies by incorporating additional factors for specific situations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported in part by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education 2019R1A6A3A12031316 (to K.S.K.); Grants-in-Aid for JSPS Scientific Research (KAKENHI) B 18KT0018 (to S.Iwami.), 18H01139 (to S.Iwami.), 16H04845 (to S.Iwami.), Scientific Research in Innovative Areas 20H05042 (to S.Iwami.); AMED Strategic International Brain Science Research Promotion Program (to K.A.); AMED CREST 19gm1310002 (to S.Iwami.); AMED Japan Program for Infectious Diseases Research and Infrastructure, 20wm0325007h0001 (to S.Iwami.), 20wm0325004s0201 (to S.Iwami.), 20wm0325012s0301 (to S.Iwami.), 20wm0325015s0301 (to S.Iwami.); AMED Research Program on HIV/AIDS 19fk0410023s0101 (to S.Iwami.); AMED Research Program on Emerging and Re-emerging Infectious Diseases 19fk0108050h0003 (to S.Iwami.), 19fk0108156h0001 (to S.Iwmai.), 20fk0108140s0801 (to S.Iwami.) and 20fk0108413s0301 (to S.Iwami.); AMED Program for Basic and Clinical Research on Hepatitis 19fk0210036h0502 (to S.Iwami.); AMED Program on the Innovative Development and the Application of New Drugs for Hepatitis B 19fk0310114h0103 (to S.Iwami.); JST MIRAI (to S.Iwami.); Moonshot R&D Grant Number JPMJMS2021 (to K.A. and S.Iwami.) and JPMJMS2025 (to S.Iwami.); Mitsui Life Social Welfare Foundation (to S.Iwami.); Shin-Nihon of Advanced Medical Research (to S.Iwami.); Suzuken Memorial Foundation (to S.Iwami.); Life Science Foundation of Japan (to S.Iwami.); SECOM Science and Technology Foundation (to S.Iwami.); The Japan Prize Foundation (to S.Iwami.); Daiwa Securities Health Foundation (to S.Iwami.); the MIDAS Coordination Center (MIDASSUGP2020-6) by a grant from the National Institute of General Medical Science (3U24GM132013-02S2) (to K.E.). The study does not necessarily represent the views of the funding agencies listed above.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Kissler, S. M., Fauver, J. R., Mack, C., Olesen, S. W., Tai, C., Shiue, K. Y., . . . Vogels, C. (2020). SARS-CoV-2 viral dynamics in acute infections. medRxiv. Kissler, S. M., Fauver, J. R., Mack, C., Tai, C. G., Breban, M. I., Watkins, A. E., . . . Metti, J. (2021). Densely sampled viral trajectories for SARS-CoV-2 variants alpha (B. 1.1. 7) and epsilon (B. 1.429). medRxiv, 2021.2002. 2016.21251535. Wolfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Muller, M. A., . . . Rothe, C. (2020). Virological assessment of hospitalized patients with COVID-2019. Nature, 581(7809), 465-469. Jang, S., Rhee, J.-Y., Wi, Y. M., & Jung, B. K. (2021). Viral kinetics of SARS-CoV-2 over the preclinical, clinical, and postclinical period. International Journal of Infectious Diseases, 102, 561-565. Kim, E. S., Chin, B. S., Kang, C. K., Kim, N. J., Kang, Y. M., Choi, J.-P., . . . Kim, S. E. (2020). Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19. Journal of Korean medical science, 35(13). Young, B. E., Ong, S. W. X., Kalimuddin, S., Low, J. G., Tan, S. Y., Loh, J., . . . Mak, T. M. (2020). Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. Jama, 323(15), 1488-1494. Zou, L., Ruan, F., Huang, M., Liang, L., Huang, H., Hong, Z., . . . Xia, J. (2020). SARS-CoV-2 viral load in upper respiratory specimens of infected patients. New England Journal of Medicine, 382(12), 1177-1179. Sakurai, A., Sasaki, T., Kato, S., Hayashi, M., Tsuzuki, S.-i., Ishihara, T., . . . Doi, Y. (2020). Natural history of asymptomatic SARS-CoV-2 infection. New England Journal of Medicine, 383(9), 885-886. Kam, K., Thoon, K. C., Maiwald, M., Chong, C. Y., Soong, H. Y., Loo, L. H., . . . Yung, C. F. (2021). SARS-CoV-2 viral RNA load dynamics in the nasopharynx of infected children. Epidemiology & Infection, 149. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -